BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop

Bristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two.

The company, which was testing its immuno-oncology star alongside Yervoy in previously treated patients whose disease had recurred or spread, said Thursday that the pair had failed to outdo Opdivo on its own.